Evidence map›Paper›PMID 35493548›Full record

ArticleRSC advances2021

Using dual exonucleases to finely distinguish structural adjustment of aptamers for small-molecule detection.

Lancheng Wang, Huimin Zhou, Kun Yan, Peng Xu, Bin Di, Chi Hu, Mengxiang Su

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lancheng WangDepartment of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University Nanjing 211198 P. R. China chihu@cpu.edu.cn.
Huimin ZhouDepartment of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University Nanjing 211198 P. R. China chihu@cpu.edu.cn.
Kun YanDepartment of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University Nanjing 211198 P. R. China sumengxiang@cpu.edu.cn.
Peng XuKey Laboratory of Drug Monitoring and Control, Drug Intelligence and Forensic Center, Ministry of Public Security No. 18 Dongbeiwang West Road Beijing 100193 P. R. China.
Bin DiDepartment of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University Nanjing 211198 P. R. China sumengxiang@cpu.edu.cn.ORCID https://orcid.org/0000-0002-1907-1736
Chi HuDepartment of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University Nanjing 211198 P. R. China chihu@cpu.edu.cn.ORCID https://orcid.org/0000-0002-9720-2762
Mengxiang SuDepartment of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University Nanjing 211198 P. R. China sumengxiang@cpu.edu.cn.ORCID https://orcid.org/0000-0001-7866-2942
China Pharmaceutical University · CNMinistry of Public Security of the People's Republic of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The binding of small molecules to their DNA aptamers can modulate their susceptibility to digestion by exonucleases, however, absolute differentiation between digestion and inhibition has never been reported. Here, we show that the digestion of aptamers by T7 exonuclease can be completely inhibited upon binding of small-molecule targets and exploit this finding for the first time to achieve sensitive, label-free small-molecule detection. We use a quinine-binding aptamer to show that target binding entirely halts T7 exonuclease digestion, leaving behind an intact double-stranded product that retains strong target affinity. On the contrary, digestion of nontarget-bound aptamer produces a single-stranded product incapable of target binding. Exonuclease I efficiently eliminates these single-stranded products but is unable to digest the target-bound double-stranded product. The remaining products can be fluorescently quantified with SYBR Gold to determine target concentrations, giving a limit of detection of 100 nM with the linear range from 0 to 8 μM. We demonstrate the first example of a dual-exonuclease-mediated approach capable of producing a concentration-dependent response in terms of aptamer digestion modules, therefore improving performance of the current aptamer-based assay for small-molecule detection.

Identifiers

PMID35493548
PMCPMC9042303
OpenAlexW3203147607

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.